Cognition Therapeutics Inc. (CGTX)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Cognition Therapeutics, Inc. (CGTX) Q4 2025 Earnings Call Transcript
Cognition Therapeutics, Inc. (CGTX) Q4 2025 Earnings Call Transcript
Cognition Therapeutics (CGTX) Moves to Buy: Rationale Behind the Upgrade
Cognition Therapeutics (CGTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Cognition: Zervimesine AD Treatment Program FDA Alignment Means "Strong Buy" Rating
I rate Cognition Therapeutics a "Strong Buy" due to FDA alignment on two pivotal phase 3 trials zervimesine in mild-to-moderate Alzheimer's patients with low p-tau217; Successful results means NDA filing. Zervimesine showed a remarkable 95% slowing of cognitive decline in the low-ptau217 biomarker-defined subgroup, supporting a precision medicine approach and strong phase 3 prospects. The company is well-financed through government grants and has multiple funding options, with operational funding into Q2 2026, reducing near-term dilution risk.
Cognition Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| RF Rekah Franca Catalyst Funds Management Pty Ltd. | 52,800 | $40,102 | $50,064.96 | $9,962.96 | 24.84% |
| HFT Hui Fai Tam Caitong International Asset Management Co. Ltd. | 1 | $1.35 | $0.94 | -$0.41 | -30.37% |
 Matthew Okkerse Dauntless Investment Group LLC | 431,000 | $581,850 | $404,191.8 | -$177,658.2 | -30.53% |
Cognition Therapeutics Inc. (CGTX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Cognition Therapeutics Inc. ever had a stock split?
Cognition Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Lisa Ricciardi CEO | NASDAQ (CM) Exchange | 19243B102 CUSIP |
| US Country | 14 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Cognition Therapeutics, Inc. is a pioneering clinical-stage biopharmaceutical enterprise dedicated to the discovery and development of small molecule therapeutics aimed at combating age-related degenerative diseases and disorders affecting the central nervous system and retina. A standout in the field of neurodegenerative disease management, the company integrates innovative scientific approaches with a deep understanding of the challenges posed by conditions such as Alzheimer's disease and age-related macular degeneration. Since its inception in 2007 and with its headquarters nestled in Purchase, New York, Cognition Therapeutics has been at the forefront of creating potent treatments designed to cross the blood-brain barrier, a critical factor in the effectiveness of neurodegenerative disease treatments.
Products and Services
- CT1812 - CT1812 represents the leading edge of Cognition Therapeutics' innovative product pipeline. It is an orally administered molecule that has been meticulously designed to modulate the S2R complex. By selectively binding to this complex, CT1812 exhibits promise in penetrating the blood-brain barrier—a feat that could revolutionize treatment modalities for various neurodegenerative conditions.
This advanced therapeutic candidate is currently under Phase 2 clinical trials, demonstrating its potential efficacy in addressing Alzheimer's disease by targeting the underlying molecular pathways associated with cognitive decline. Additionally, CT1812 is being explored for its capability to treat other significant neurological conditions, including geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies such as dementia with Lewy bodies. The development and clinical trials of CT1812 underscore Cognition Therapeutics' commitment to addressing unmet medical needs in the realm of neurodegenerative diseases and visual disorders, paving the way for potentially groundbreaking treatments.
